At a glance
What is it—and why does it matter?
An introduction is not yet available. The findings below address specific research questions, not a complete account of this peptide.
This published profile is a reference in progress. Findings retain their source context; missing topics are marked below.
What is it?
A molecule, not a product name.
Identity
Pentosan polysulfate sodium is described as a semi-synthetic, heparin-like macromolecular carbohydrate derivative with chemical and structural similarity to glycosaminoglycans.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“Pentosan polysulfate sodium is a semi-synthetically produced heparin-like macromolecular carbohydrate derivative, which chemically and structurally resembles glycosaminoglycans.”
ELMIRON®100 MG(PENTOSAN POLYSULFATE SODIUM)CAPSULES · DESCRIPTION
dailymed:f0ba651e-3d8a-11df-8fbe-119855d89593:d135d76fd516:d135d76fd516
Identity
The abstract explicitly equates pentosan polysulfate sodium (PPS) with the name Elmiron.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“While bladder fulguration and pentosan polysulfate sodium (PPS, Elmiron) are established treatments”
Impact of Elmiron adjunct therapy on outcomes of fulguration in chronic interstitial cystitis in women. · Abstract
pubmed:41578241:f88f7a4b6877:f88f7a4b6877
How does it work?
Target, response, and disposition.
Mechanism
PPS is reported to bind or otherwise interact with PF4, a protein implicated in heparin-associated thrombocytopenia mechanisms.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“and also interacts with platelet factor 4 (PF4)”
Pentosan Polysulfate and Heparin Exhibit Comparable Interactions with Platelet Factor 4, Suggesting a Potential Risk of Thrombocytopenia. · Abstract
pubmed:41658182:80815a5493e3:80815a5493e3
Mechanism
The study operationalized visual acuity by applying conversion methods (e.g., Snellen to logMAR and letter scores) to identify best documented VA.
1 cited source · 1 linked study ID
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“Best documented VA was evaluated using VA conversion methods (e.g. from Snellen chart VA to logMAR units and letters).”
Retrospective study of visual acuity changes in patients with interstitial cystitis receiving pentosan polysulfate sodium. · METHODS
pubmed:41989996:3ab7e370d278:3ab7e370d278
Mechanism
The study methodology involved longitudinal follow-up of two patients using repeated ophthalmic examinations and multimodal fundus imaging.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“Two patients followed with serial ophthalmic examination and multimodal fundus imaging.”
Late Development of Clinically Apparent Pentosan Polysulfate Maculopathy after Drug Cessation. · METHODS
pubmed:41920598:71d3e1411729:71d3e1411729
Mechanism
The work assesses FLIO imaging signals in PPS maculopathy and compares/correlates them with other retinal imaging modalities (FAF and OCT).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“This study evaluated fluorescence lifetime imaging ophthalmoscopy (FLIO) in PPS maculopathy patients and correlated findings with fundus autofluorescence (FAF) and optical coherence tomography (OCT).”
Characterization of Pentosan Polysulfate Sodium Maculopathy With Fluorescence Lifetime Imaging. · PURPOSE
pubmed:42138584:3eecda95bfb0:3eecda95bfb0
Mechanism
The design is prospective and enrolls individuals diagnosed with PPS maculopathy at a single institution (University of California, San Diego).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“This prospective study included patients with confirmed PPS maculopathy at the University of California, San Diego.”
Characterization of Pentosan Polysulfate Sodium Maculopathy With Fluorescence Lifetime Imaging. · METHODS
pubmed:42138584:3eecda95bfb0:3eecda95bfb0
Mechanism
The label states that the mechanism of action in interstitial cystitis has not been established.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“The mechanism of action of pentosan polysulfate sodium in interstitial cystitis is not known.”
ELMIRON®100 MG(PENTOSAN POLYSULFATE SODIUM)CAPSULES · General
dailymed:f0ba651e-3d8a-11df-8fbe-119855d89593:d135d76fd516:d135d76fd516
Mechanism
PPS forms complexes with PF4.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“despite PPS forming complexes with PF4”
Pentosan Polysulfate and Heparin Exhibit Comparable Interactions with Platelet Factor 4, Suggesting a Potential Risk of Thrombocytopenia. · Abstract
pubmed:41658182:80815a5493e3:80815a5493e3
Mechanism
The abstract’s objective is to evaluate adjunctive Elmiron as an add-on to fulguration to see if it enhances measured therapeutic outcomes in a specific patient group.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“To evaluate whether adjunctive Elmiron therapy enhances the therapeutic outcomes of fulguration in female patients with Hunner-type IC.”
Impact of Elmiron adjunct therapy on outcomes of fulguration in chronic interstitial cystitis in women. · Abstract
pubmed:41578241:f88f7a4b6877:f88f7a4b6877
Mechanism
The research design was retrospective and observational (non-interventional), leveraging registry and claims/health databases over 1 January 2015 to 1 March 2021.
1 cited source · 1 linked study ID
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“This retrospective, non-interventional cohort study (NCT05179460) using data from the American Academy of Ophthalmology IRIS (Intelligent Research in Sight) Registry and Komodo Health database from 1 January 2015 to 1 March 2021 assessed VA changes in two matched cohorts of IC patients: "PPS-Exposed Cohort," and "Non-PPS-exposed Cohort."”
Retrospective study of visual acuity changes in patients with interstitial cystitis receiving pentosan polysulfate sodium. · METHODS
pubmed:41989996:3ab7e370d278:3ab7e370d278
Mechanism
Outcome ascertainment used masked expert grading of multimodal retinal imaging with predefined criteria and adjudication, reducing observer bias in this retrospective review.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“Two masked retina specialists evaluated available multimodal imaging for pigmentary maculopathy using the established criteria, with any disagreements adjudicated by a third reviewer.”
Pigmentary Maculopathy in Patients with Interstitial Cystitis: Association with Pentosan Polysulfate and Other Therapies. · METHODS
pubmed:41049115:a984012a8824:a984012a8824
Mechanism
Atomic force microscopy is reported to corroborate the molecular-weight-dependent increase in PPS–PF4 interaction strength.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“and the same trend was confirmed by atomic force microscopy.”
Pentosan Polysulfate and Heparin Exhibit Comparable Interactions with Platelet Factor 4, Suggesting a Potential Risk of Thrombocytopenia. · Abstract
pubmed:41658182:80815a5493e3:80815a5493e3
Pharmacokinetics
Using urinary radioactivity as the basis, the mean estimated systemic absorption of an oral radiolabeled dose was approximately 6%.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“Based on urinary excretion of radioactivity, a mean of approximately 6% of a radiolabeled oral dose of pentosan polysulfate sodium is absorbed and reaches the systemic circulation.”
ELMIRON®100 MG(PENTOSAN POLYSULFATE SODIUM)CAPSULES · Absorption
dailymed:f0ba651e-3d8a-11df-8fbe-119855d89593:d135d76fd516:d135d76fd516
Pharmacokinetics
In healthy subjects given radiolabeled oral solution doses, fecal excretion accounted for a large fraction of dose as unchanged drug, differing between 300 mg and 450 mg groups.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“A large proportion of the orally administered dose of pentosan polysulfate sodium (mean 84% in the 300 mg group and 58% in the 450 mg group) is excreted in feces as unchanged drug.”
ELMIRON®100 MG(PENTOSAN POLYSULFATE SODIUM)CAPSULES · Excretion
dailymed:f0ba651e-3d8a-11df-8fbe-119855d89593:d135d76fd516:d135d76fd516
Pharmacokinetics
A radiolabeled clinical pharmacology study in fasted healthy female volunteers reported a median time of 2 hours to maximal plasma radioactivity after single oral 300 or 450 mg dosing.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“In a clinical pharmacology study in which healthy female volunteers received a single oral 300 or 450 mg dose of pentosan polysulfate sodium containing radiolabeled drug as a solution under fasted conditions, maximal levels of plasma radioactivity were seen approximately at a median of 2 hours (range 0.6-120 hours) after dosing.”
ELMIRON®100 MG(PENTOSAN POLYSULFATE SODIUM)CAPSULES · Absorption
dailymed:f0ba651e-3d8a-11df-8fbe-119855d89593:d135d76fd516:d135d76fd516
What has been studied?
What the evidence says.
Comparative evidence
In an age-stratified comparison, voiding volume changed in a less favorable direction in the younger-than-65 group than in the older-than-65 group, with statistical significance.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“Compared to patients older than 65 years, those younger than 65 years showed significantly better improvements in the IPSS (-0.492 vs. -0.184,P= 0.018) but worse in voiding volume (-2.481 vs. 5.032,P= 0.006).”
Efficacy and safety of pentosan polysulfate therapy in patients with interstitial cystitis for relief of lower urinary tract symptoms: 15-year single center experience. · RESULTS
pubmed:41472923:c45e9adab638:c45e9adab638
Comparative evidence
The control/comparator group in this analysis consisted of patients who did not receive adjunctive Elmiron following fulguration.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“while Group 2 (n = 48) did not.”
Impact of Elmiron adjunct therapy on outcomes of fulguration in chronic interstitial cystitis in women. · Abstract
pubmed:41578241:f88f7a4b6877:f88f7a4b6877
Comparative evidence
An age-stratified comparison reports a statistically greater IPSS improvement in the younger-than-65 group compared with the older-than-65 group.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“Compared to patients older than 65 years, those younger than 65 years showed significantly better improvements in the IPSS (-0.492 vs. -0.184,P= 0.018) but worse in voiding volume (-2.481 vs. 5.032,P= 0.006).”
Efficacy and safety of pentosan polysulfate therapy in patients with interstitial cystitis for relief of lower urinary tract symptoms: 15-year single center experience. · RESULTS
pubmed:41472923:c45e9adab638:c45e9adab638
Comparative evidence
The analysis uses matched controls (age, sex, lens status) to contextualize FLIO measurements in PPS maculopathy.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“FLIO data were compared to age-, sex- and lens-status-matched controls.”
Characterization of Pentosan Polysulfate Sodium Maculopathy With Fluorescence Lifetime Imaging. · METHODS
pubmed:42138584:3eecda95bfb0:3eecda95bfb0
Study findings
In this retrospective PPS maculopathy series, over follow-up, stage progression occurred in 37.5% of eyes.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“Overall, 37.5% of eyes showed progression of maculopathy stage, and cRORA was present in 75% of eyes at last follow-up.”
Spectrum of Colopathy and Severe Polyposis Associated With Pentosan Polysulfate Sodium Maculopathy: A Retrospective Case Series. · RESULTS
pubmed:41785987:1bfa6415ea64:1bfa6415ea64
Study findings
The authors conclude PPS improved clinical pain, joint function, and cartilage volume compared with placebo, and cite biomarker changes at weeks 8 and 26 as supporting evidence.
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“PPS-treated dogs experienced improvements in pain, joint function, and cartilage volume compared to placebo, supported by changes in biomarkers at weeks 8 and 26.”
Effects of pentosan polysulfate sodium on joint structure and function out to six months in naturally-occurring canine osteoarthritis. · CONCLUSIONS
pubmed:41666203:c8506754641f:c8506754641f
Study findings
Uroflowmetry voiding volume was not significantly different over time following PPS treatment.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“For UFM parameters, postvoid residual decreased significantly over time (-1.052,P= 0.029), while maximum flow rate (0.093,P= 0.334) and voiding volume (0.751,P= 0.586) showed no significant differences.”
Efficacy and safety of pentosan polysulfate therapy in patients with interstitial cystitis for relief of lower urinary tract symptoms: 15-year single center experience. · RESULTS
pubmed:41472923:c45e9adab638:c45e9adab638
Study findings
In this case series, PPS maculopathy stage distribution at last follow-up shifted toward higher stages compared with presentation.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“At final follow-up, 25% of eyes were stage 1, 50% stage 2, and 25% stage 3.”
Spectrum of Colopathy and Severe Polyposis Associated With Pentosan Polysulfate Sodium Maculopathy: A Retrospective Case Series. · RESULTS
pubmed:41785987:1bfa6415ea64:1bfa6415ea64
Study findings
This retrospective cohort found that PPS-exposed patients were more likely to have amitriptyline exposure, indicating confounding by co-therapies may be relevant when assessing maculopathy associations.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“Patients with PPS exposure had increased odds of exposure to hydroxyzine (odds ratio [OR]: 4.76,P< 0.0001), amitriptyline (OR: 2.62,P< 0.0002)”
Pigmentary Maculopathy in Patients with Interstitial Cystitis: Association with Pentosan Polysulfate and Other Therapies. · RESULTS
pubmed:41049115:a984012a8824:a984012a8824
Study findings
Functional outcome: gait symmetry normalized through week 26 in the PPS-treated group, interpreted in the text as reduced lameness and improved function.
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“The PPS-treated group experienced normalization of gait symmetry up to week 26, indicating a reduction in lameness and an improvement in overall function.”
Effects of pentosan polysulfate sodium on joint structure and function out to six months in naturally-occurring canine osteoarthritis. · RESULTS
pubmed:41666203:c8506754641f:c8506754641f
Study findings
Within the <800 g subgroup, maculopathy presence was associated with higher cumulative dose normalized to body weight compared with no maculopathy.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“In low-exposure cases (<800 g), those with maculopathy were older (67.1 vs 56.9 years, P = .01), had longer PPS exposure (11 vs 7.9 years, P = .03), a greater dose per body weight (9.7 vs 5.1 g/kg, P < .001)”
Risk factors for pentosan polysulfate maculopathy. · RESULTS
pubmed:41962908:840ed7d52888:840ed7d52888
Study findings
Adjusted analysis indicated sustained reductions in HCPI (a chronic pain index) at 26 weeks in PPS-treated dogs compared with placebo.
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“PPS-treated dogs experienced sustained HCPI reductions compared to placebo at 26 weeks after adjusting for differences in baseline pain.”
Effects of pentosan polysulfate sodium on joint structure and function out to six months in naturally-occurring canine osteoarthritis. · RESULTS
pubmed:41666203:c8506754641f:c8506754641f
Study findings
Within this interstitial cystitis cohort, PPS exposure status was associated with differential co-medication use; hydroxyzine exposure was more common among those exposed to PPS by odds ratio.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“Patients with PPS exposure had increased odds of exposure to hydroxyzine (odds ratio [OR]: 4.76,P< 0.0001)”
Pigmentary Maculopathy in Patients with Interstitial Cystitis: Association with Pentosan Polysulfate and Other Therapies. · RESULTS
pubmed:41049115:a984012a8824:a984012a8824
Study findings
The abstract reports a statistically significant between-group difference favoring Elmiron for reduction of the Interstitial Cystitis Problem Index (ICPI) at 6 months compared with no Elmiron.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“in ICPI scores at both 6 months (p = 0.040)”
Impact of Elmiron adjunct therapy on outcomes of fulguration in chronic interstitial cystitis in women. · Abstract
pubmed:41578241:f88f7a4b6877:f88f7a4b6877
Study findings
In PPS maculopathy, the abstract highlights functional visual symptoms including poor dark adaptation and worsening central vision over time.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“Affected individuals often experience impaired dark adaptation and progressive central vision loss.”
Pentosan polysulfate maculopathy: clinical considerations, pathobiology, and causality. · Abstract
pubmed:40962246:90cf14d08772:90cf14d08772
Study findings
In the reported results, subcutaneous iPPS was linked to changes in synovial fluid biomarker levels measured at Day 56.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“Subcutaneous iPPS treatment was associated with altered synovial fluid biomarkers at Day 56.”
Effects of pentosan polysulfate sodium on synovial fluid biomarkers in moderate to severe knee osteoarthritis: an exploratory, phase 2, randomized, double-blind, placebo-controlled trial. · RESULTS
pubmed:41588475:ec022a0712b2:ec022a0712b2
Study findings
Within the <800 g cumulative exposure subgroup, maculopathy status was associated with higher age compared with no maculopathy.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“In low-exposure cases (<800 g), those with maculopathy were older (67.1 vs 56.9 years, P = .01)”
Risk factors for pentosan polysulfate maculopathy. · RESULTS
pubmed:41962908:840ed7d52888:840ed7d52888
Study findings
In this retrospective case series of PPS maculopathy, GI evaluation by colonoscopy frequently identified severe adenomatous polyposis (6/8 patients, 75%).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“Colonoscopy revealed severe adenomatous polyposis in 6 of the 8 patients (75%), with 3 requiring partial or total colectomy and 2 undergoing endoscopic resection.”
Spectrum of Colopathy and Severe Polyposis Associated With Pentosan Polysulfate Sodium Maculopathy: A Retrospective Case Series. · RESULTS
pubmed:41785987:1bfa6415ea64:1bfa6415ea64
Study findings
Imaging outcome: MRI-assessed total cartilage volume increased at weeks 8 and 26 versus baseline in the PPS arm relative to placebo.
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“Total cartilage volume increased at weeks 8 and 26 from baseline in the PPS-treated group compared to placebo”
Effects of pentosan polysulfate sodium on joint structure and function out to six months in naturally-occurring canine osteoarthritis. · RESULTS
pubmed:41666203:c8506754641f:c8506754641f
Study findings
Baseline imbalance: the PPS arm started with higher HCPI-measured pain than the placebo arm (15.14 vs 8.83).
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“At baseline, the PPS-treated group had higher pain with Helsinki Chronic Pain Index (HCPI) scores of 15.14 compared to 8.83 in placebo.”
Effects of pentosan polysulfate sodium on joint structure and function out to six months in naturally-occurring canine osteoarthritis. · RESULTS
pubmed:41666203:c8506754641f:c8506754641f
Study findings
In this retrospective analysis, postoperative adjunctive Elmiron (given for 6 months) did not produce statistically significant differences between groups on the Visual Analogue Scale (VAS) at any measured time point compared with no Elmiron.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“No statistically significant differences were observed between groups in VAS scores at any time point.”
Impact of Elmiron adjunct therapy on outcomes of fulguration in chronic interstitial cystitis in women. · Abstract
pubmed:41578241:f88f7a4b6877:f88f7a4b6877
Study findings
Within the <800 g subgroup, maculopathy presence was associated with longer duration of PPS exposure compared with those without maculopathy.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“In low-exposure cases (<800 g), those with maculopathy were older (67.1 vs 56.9 years, P = .01), had longer PPS exposure (11 vs 7.9 years, P = .03)”
Risk factors for pentosan polysulfate maculopathy. · RESULTS
pubmed:41962908:840ed7d52888:840ed7d52888
Study findings
Uroflowmetry results indicate a statistically significant reduction in postvoid residual over time following PPS treatment.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“For UFM parameters, postvoid residual decreased significantly over time (-1.052,P= 0.029), while maximum flow rate (0.093,P= 0.334) and voiding volume (0.751,P= 0.586) showed no significant differences.”
Efficacy and safety of pentosan polysulfate therapy in patients with interstitial cystitis for relief of lower urinary tract symptoms: 15-year single center experience. · RESULTS
pubmed:41472923:c45e9adab638:c45e9adab638
Study findings
A matched cohort analysis comparing exposed vs non-exposed interstitial cystitis patients reported no evidence that pentosan polysulfate sodium exposure affected visual acuity progression during 36 months of follow-up.
1 cited source · 1 linked study ID
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“Over the 36 months of follow-up period, this matched cohort analysis found no supporting evidence that PPS exposure in IC patients impacted the progression of VA compared to those patients not exposed to PPS.”
Retrospective study of visual acuity changes in patients with interstitial cystitis receiving pentosan polysulfate sodium. · CONCLUSIONS
pubmed:41989996:3ab7e370d278:3ab7e370d278
Study findings
Relative to placebo at Day 56, iPPS was associated with a negative adjusted change-from-baseline least squares mean difference for COMP, reported as a percent difference with interval (-62.60, 15.40).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“In iPPS-treated versus placebo-treated participants at Day 56, the adjusted change from baseline least squares mean difference of cartilage metabolism markers COMP and ARGS decreased -23.60% (-62.60, 15.40) and -56.60% (-106.59, -6.62; p = 0.028), respectively.”
Effects of pentosan polysulfate sodium on synovial fluid biomarkers in moderate to severe knee osteoarthritis: an exploratory, phase 2, randomized, double-blind, placebo-controlled trial. · RESULTS
pubmed:41588475:ec022a0712b2:ec022a0712b2
Study findings
The authors conclude FLIO has potential clinical utility as a non-invasive modality for diagnosis and longitudinal monitoring in PPS maculopathy.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“FLIO is a promising non-invasive tool for diagnosing and monitoring PPS maculopathy.”
Characterization of Pentosan Polysulfate Sodium Maculopathy With Fluorescence Lifetime Imaging. · CONCLUSION
pubmed:42138584:3eecda95bfb0:3eecda95bfb0
Study findings
In the reported PPS maculopathy case series, management of severe adenomatous polyposis included colectomy (3 patients) and endoscopic resection (2 patients).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“Colonoscopy revealed severe adenomatous polyposis in 6 of the 8 patients (75%), with 3 requiring partial or total colectomy and 2 undergoing endoscopic resection.”
Spectrum of Colopathy and Severe Polyposis Associated With Pentosan Polysulfate Sodium Maculopathy: A Retrospective Case Series. · RESULTS
pubmed:41785987:1bfa6415ea64:1bfa6415ea64
Study findings
Within the <800 g subgroup, maculopathy presence was associated with lower body weight compared with those without maculopathy.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“In low-exposure cases (<800 g), those with maculopathy were older (67.1 vs 56.9 years, P = .01), had longer PPS exposure (11 vs 7.9 years, P = .03), a greater dose per body weight (9.7 vs 5.1 g/kg, P < .001), and lower body weight (63.9 vs 74.4 kg, P = .03).”
Risk factors for pentosan polysulfate maculopathy. · RESULTS
pubmed:41962908:840ed7d52888:840ed7d52888
Study findings
In this retrospective PPS maculopathy case series, the median interval from PPS initiation to GI diagnosis was 10 years.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“The median latency to GI diagnosis was 10 years after PPS initiation.”
Spectrum of Colopathy and Severe Polyposis Associated With Pentosan Polysulfate Sodium Maculopathy: A Retrospective Case Series. · RESULTS
pubmed:41785987:1bfa6415ea64:1bfa6415ea64
Study findings
In this retrospective study subset with multimodal retinal imaging, all identified pigmentary maculopathy cases were in the PPS-exposed group, suggesting an exposure-associated pattern in the sampled clinic population.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“Of the 122 patients with retinal imaging (71 with PPS exposure, 51 without), 8 patients (16 eyes) were graded to have pigmentary maculopathy and all 8 patients had PPS exposure.”
Pigmentary Maculopathy in Patients with Interstitial Cystitis: Association with Pentosan Polysulfate and Other Therapies. · RESULTS
pubmed:41049115:a984012a8824:a984012a8824
Study findings
Within this retrospective PPS maculopathy cohort, ulcerative colitis occurred in one patient.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“One patient developed ulcerative colitis, and 2 additional patients were diagnosed with Crohn's disease or microscopic colitis.”
Spectrum of Colopathy and Severe Polyposis Associated With Pentosan Polysulfate Sodium Maculopathy: A Retrospective Case Series. · RESULTS
pubmed:41785987:1bfa6415ea64:1bfa6415ea64
Study findings
The results report a statistically significant longitudinal improvement in QoL after oral PPS, with a plateau by 3 months.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“There were significant gains in total IPSS (-0.335,P< 0.001) and QoL (-0.061,P< 0.001) over time, achieving stable phase within 3 months from the initiation of PPS treatment.”
Efficacy and safety of pentosan polysulfate therapy in patients with interstitial cystitis for relief of lower urinary tract symptoms: 15-year single center experience. · RESULTS
pubmed:41472923:c45e9adab638:c45e9adab638
Study findings
Within PPS maculopathy, fluorescence lifetime measures on FLIO are statistically associated with severity grading.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“Lifetimes also varied significantly with maculopathy severity (p<0.05).”
Characterization of Pentosan Polysulfate Sodium Maculopathy With Fluorescence Lifetime Imaging. · RESULTS
pubmed:42138584:3eecda95bfb0:3eecda95bfb0
Study findings
The abstract reports a statistically significant greater reduction in Interstitial Cystitis Problem Index (ICPI) at 12 months in the Elmiron group compared with no Elmiron.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“and 12 months (p < 0.001)”
Impact of Elmiron adjunct therapy on outcomes of fulguration in chronic interstitial cystitis in women. · Abstract
pubmed:41578241:f88f7a4b6877:f88f7a4b6877
Study findings
This retrospective analysis using linear mixed models reports a statistically significant longitudinal decrease (improvement) in total IPSS after oral PPS, with a plateau by 3 months.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“There were significant gains in total IPSS (-0.335,P< 0.001) and QoL (-0.061,P< 0.001) over time, achieving stable phase within 3 months from the initiation of PPS treatment.”
Efficacy and safety of pentosan polysulfate therapy in patients with interstitial cystitis for relief of lower urinary tract symptoms: 15-year single center experience. · RESULTS
pubmed:41472923:c45e9adab638:c45e9adab638
Study findings
In this PPS maculopathy case series, baseline severity (by stage) was mostly stage 1, with fewer stage 2 and stage 3 eyes.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“At presentation, 62.5% of eyes were stage 1, 31.3% stage 2, and 6.3% stage 3.”
Spectrum of Colopathy and Severe Polyposis Associated With Pentosan Polysulfate Sodium Maculopathy: A Retrospective Case Series. · RESULTS
pubmed:41785987:1bfa6415ea64:1bfa6415ea64
Study findings
Uroflowmetry maximum flow rate was not significantly different over time following PPS treatment.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“For UFM parameters, postvoid residual decreased significantly over time (-1.052,P= 0.029), while maximum flow rate (0.093,P= 0.334) and voiding volume (0.751,P= 0.586) showed no significant differences.”
Efficacy and safety of pentosan polysulfate therapy in patients with interstitial cystitis for relief of lower urinary tract symptoms: 15-year single center experience. · RESULTS
pubmed:41472923:c45e9adab638:c45e9adab638
Study findings
The label attributes anticoagulant activity and fibrinolytic effects to pentosan polysulfate sodium.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“It has anticoagulant and fibrinolytic effects.”
ELMIRON®100 MG(PENTOSAN POLYSULFATE SODIUM)CAPSULES · General
dailymed:f0ba651e-3d8a-11df-8fbe-119855d89593:d135d76fd516:d135d76fd516
Study findings
A blinded RCT in chronic interstitial cystitis reported a higher proportion achieving >50% bladder pain improvement with ELMIRON 100 mg TID over 3 months compared with placebo, with p = 0.005.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“In this study, 28/74 (38%) of patients who received ELMIRON®and 13/74 (18%) of patients who received placebo showed greater than 50% improvement in bladder pain (p = 0.005).”
ELMIRON®100 MG(PENTOSAN POLYSULFATE SODIUM)CAPSULES · CLINICAL TRIALS
dailymed:f0ba651e-3d8a-11df-8fbe-119855d89593:d135d76fd516:d135d76fd516
Study findings
Compared with placebo at Day 56, iPPS was associated with a decrease in ARGS, reported as an adjusted percent least squares mean difference with p = 0.028.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“In iPPS-treated versus placebo-treated participants at Day 56, the adjusted change from baseline least squares mean difference of cartilage metabolism markers COMP and ARGS decreased -23.60% (-62.60, 15.40) and -56.60% (-106.59, -6.62; p = 0.028), respectively.”
Effects of pentosan polysulfate sodium on synovial fluid biomarkers in moderate to severe knee osteoarthritis: an exploratory, phase 2, randomized, double-blind, placebo-controlled trial. · RESULTS
pubmed:41588475:ec022a0712b2:ec022a0712b2
Risks and interactions
Risks, organized for scanning.
Interactions
A controlled interaction study reported no meaningful difference in INR between warfarin plus placebo and warfarin plus pentosan polysulfate sodium (100 mg capsule every 8 hours for 7 days) when warfarin was titrated to INR 1.4 to 1.8.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“INR for warfarin + placebo and warfarin + pentosan polysulfate sodium were comparable.”
ELMIRON®100 MG(PENTOSAN POLYSULFATE SODIUM)CAPSULES · Drug-Drug Interactions
dailymed:f0ba651e-3d8a-11df-8fbe-119855d89593:d135d76fd516:d135d76fd516
Safety findings
A labeled safety warning reports retinal pigmentary changes (described as pigmentary maculopathy) identified with long-term ELMIRON use.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“Pigmentary changes in the retina, reported in the literature as pigmentary maculopathy, have been identified with long-term use of ELMIRON®(seeADVERSE REACTIONS).”
ELMIRON®100 MG(PENTOSAN POLYSULFATE SODIUM)CAPSULES · WARNINGS
dailymed:f0ba651e-3d8a-11df-8fbe-119855d89593:d135d76fd516:d135d76fd516
Products and regulatory status
Same ingredient. Different records.
Regulatory status
The labeled indication is symptom relief (bladder pain or discomfort) in interstitial cystitis.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“ELMIRON®(pentosan polysulfate sodium) is indicated for the relief of bladder pain or discomfort associated with interstitial cystitis.”
ELMIRON®100 MG(PENTOSAN POLYSULFATE SODIUM)CAPSULES · INDICATIONS AND USAGE
dailymed:f0ba651e-3d8a-11df-8fbe-119855d89593:d135d76fd516:d135d76fd516
Administration context
The practical clinical context.
Administration
The product is an oral capsule formulation containing 100 mg pentosan polysulfate sodium per capsule.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“ELMIRON®is supplied in white, opaque hard gelatin capsules containing 100 mg pentosan polysulfate sodium, microcrystalline cellulose, and magnesium stearate.”
ELMIRON®100 MG(PENTOSAN POLYSULFATE SODIUM)CAPSULES · DESCRIPTION
dailymed:f0ba651e-3d8a-11df-8fbe-119855d89593:d135d76fd516:d135d76fd516
Additional research & classification gaps
18 archived statements are kept separate from drug-effect findings. Media studies, economic models, methods, and records with unresolved scope are not used as medical-effect evidence.
Inspect contextual research (18)
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The evaluation benchmarked multimodal large language model responses against human retinal specialist responses using standardized prompts informed by multimodal imaging and demographics, including PPS maculopathy cases.
Research context only—not evidence of a treatment effect.
- Evaluating the clinical utility of multimodal large language models in rare maculopathy.
Four MLLMs (ChatGPT-4o, Claude 3.5 Sonnet, Google Gemini 1.5 Pro, Perplexity Llama 3.1 Sonar/Default) along with human retinal specialists answered prompts based on retinal imaging and demographic data.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The source compares complex size, stating PPS fraction complexes are smaller than complexes formed with UFH and LMWH.
Research context only—not evidence of a treatment effect.
- Pentosan Polysulfate and Heparin Exhibit Comparable Interactions with Platelet Factor 4, Suggesting a Potential Risk of Thrombocytopenia.
the complexes formed with PPS fractions being smaller than those formed with UFH and LMWH
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The abstract reports a duration-dependent increase in PINK1 expression with PPS exposure.
Research context only—not evidence of a treatment effect.
- Retinal Pigment Epithelium Injury in Pentosan Polysulfate Exposure: Morphologic Changes, Phagocytic Deficits, and Mitochondrial Dysfunction.
PINK1 expression increased with increasing duration of exposure to PPS.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The abstract reports dose-related functional impairment in RPE cells, with higher PPS doses associated with impaired phagocytosis measured by phagocytosis assays.
Research context only—not evidence of a treatment effect.
- Retinal Pigment Epithelium Injury in Pentosan Polysulfate Exposure: Morphologic Changes, Phagocytic Deficits, and Mitochondrial Dysfunction.
impaired phagocytosis with higher doses of PPS.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The abstract reports a dose-related impairment of mitochondrial respiration parameters (basal and maximal respiration) measured by Seahorse assay in ARPE-19 cells exposed to PPS.
Research context only—not evidence of a treatment effect.
- Retinal Pigment Epithelium Injury in Pentosan Polysulfate Exposure: Morphologic Changes, Phagocytic Deficits, and Mitochondrial Dysfunction.
increased doses of PPS impaired basal and maximal respiration in a Seahorse assay
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Constraining the response option set (restricted answer choices) improved multimodal large language model diagnostic performance metrics (accuracy and sensitivity) in this evaluation that included PPS maculopathy cases.
Research context only—not evidence of a treatment effect.
- Evaluating the clinical utility of multimodal large language models in rare maculopathy.
MLLMs showed improved accuracy and sensitivity when answer choices were restricted, with ChatGPT consistently performing best when all imaging modalities were prompted together.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Pentosan polysulfate (PPS) is described as a semisynthetic sulfated polysaccharide.
Research context only—not evidence of a treatment effect.
- Retinal Pigment Epithelium Injury in Pentosan Polysulfate Exposure: Morphologic Changes, Phagocytic Deficits, and Mitochondrial Dysfunction.
Pentosan polysulfate (PPS) is a semisynthetic sulfated polysaccharide
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
PPS is described as a heparin-like, sulfated polysaccharide, and its stated clinical indication is interstitial cystitis/bladder pain syndrome.
Research context only—not evidence of a treatment effect.
- Pentosan polysulfate maculopathy: clinical considerations, pathobiology, and causality.
Pentosan polysulfate (PPS) maculopathy is a progressive, vision-threatening retinal disorder linked to prolonged use of PPS, a heparin-like sulfated polysaccharide prescribed for interstitial cystitis/bladder pain syndrome.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
PPS is described as a semisynthetic, highly sulfated polysaccharide with structural similarity to heparin.
Research context only—not evidence of a treatment effect.
- Pentosan Polysulfate and Heparin Exhibit Comparable Interactions with Platelet Factor 4, Suggesting a Potential Risk of Thrombocytopenia.
This semisynthetic highly sulfated polysaccharide shares structural similarities with heparin
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The source links thrombocytopenia to immunogenic structural features of multimeric complexes formed by heparin and PF4.
Research context only—not evidence of a treatment effect.
- Pentosan Polysulfate and Heparin Exhibit Comparable Interactions with Platelet Factor 4, Suggesting a Potential Risk of Thrombocytopenia.
Thrombocytopenia arises from an immune response to structural features of multimeric complexes of heparin and PF4
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Time-to-onset analyses summarize when events occur after exposure; Kaplan–Meier is nonparametric survival analysis and Weibull modeling can characterize hazard-rate changes over time.
Research context only—not evidence of a treatment effect.
- Post-marketing safety of pentosan polysulfate sodium: a 21-year pharmacovigilance analysis of the FAERS database.
A gender-specific analysis was also performed. The time-to-onset (TTO) of ADEs was evaluated through descriptive statistics, the Kaplan-Meier method, and Weibull parametric modeling.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In a cell-culture model using ARPE-19 cells, PPS exposure is reported to increase mitochondrial superoxide accumulation (a mitochondrial reactive oxygen species signal).
Research context only—not evidence of a treatment effect.
- Retinal Pigment Epithelium Injury in Pentosan Polysulfate Exposure: Morphologic Changes, Phagocytic Deficits, and Mitochondrial Dysfunction.
We found that PPS increased mitochondrial superoxide accumulation
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The abstract describes a characteristic structural imaging finding—hyperpigmented macular clumps localized to the RPE—in PPS maculopathy.
Research context only—not evidence of a treatment effect.
- Pentosan polysulfate maculopathy: clinical considerations, pathobiology, and causality.
Fundus imaging commonly reveals hyperpigmented macular clumps at the level of the retinal pigment epithelium (RPE),
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The authors interpret very short lifetime foci on FLIO as potentially marking early-stage or phenotypically distinct features of PPS maculopathy (hypothesis-level language: "may").
Research context only—not evidence of a treatment effect.
- Characterization of Pentosan Polysulfate Sodium Maculopathy With Fluorescence Lifetime Imaging.
Discrete very short lifetime foci may represent early or distinct disease features.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
A characteristic imaging phenotype mentioned is an abnormal posterior-fundus autofluorescence pattern in PPS maculopathy.
Research context only—not evidence of a treatment effect.
- Pentosan polysulfate maculopathy: clinical considerations, pathobiology, and causality.
and a distinctive pattern of autofluorescence abnormality in the posterior fundus.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Using a retrospective dataset of clinical records plus multimodal retinal imaging, the study evaluated multimodal large language models’ ability to perform diagnostic classification specifically including PPS maculopathy versus phenotypic mimics.
Research context only—not evidence of a treatment effect.
- Evaluating the clinical utility of multimodal large language models in rare maculopathy.
This study aimed to assess how multimodal large language models (MLLM) diagnose and differentiate Pentosan Polysulfate (PPS) Maculopathy from other phenotypic mimics.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Despite the association, the abstract states the pathogenesis of PPS maculopathy is not yet established.
Research context only—not evidence of a treatment effect.
- Pentosan polysulfate maculopathy: clinical considerations, pathobiology, and causality.
While the underlying pathogenic mechanism remains unclear,
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Median time-to-onset summarizes the central tendency of reported onset latencies; it is descriptive for the analyzed subset and depends on report completeness.
Research context only—not evidence of a treatment effect.
- Post-marketing safety of pentosan polysulfate sodium: a 21-year pharmacovigilance analysis of the FAERS database.
The TTO analysis (n= 297) revealed a median onset time of 1,715 days
Research status + gaps
What still needs better answers?
- No publishable claim yet for: contraindication
- 283 compiled claim(s) withheld by automated assurance: assurance_score_below_0.58 (120), assurance_score_below_0.72 (134), current_regulatory_source_required (74), extraction_ambiguity (153), high_risk_requires_regulatory_or_two_independent_sources (162), no_direct_support (254), proposal_not_staged (4)
- A source-backed introductory overview is not yet available.
These are the limits of this profile, not an exhaustive list of scientific uncertainties.
References + discovery
Open the records yourself.
- ELMIRON®100 MG(PENTOSAN POLYSULFATE SODIUM)CAPSULES ↗
dailymed · published 2024-09-18 · retrieved 2026-09-09T08:45:04Z
- Pentosan polysulfate maculopathy: clinical considerations, pathobiology, and causality. ↗
pubmed · published 2025-11-01 · retrieved 2026-09-05T09:00:33Z
- Pigmentary Maculopathy in Patients with Interstitial Cystitis: Association with Pentosan Polysulfate and Other Therapies. ↗
pubmed · published 2026-01-01 · retrieved 2026-09-05T09:00:33Z
- Evaluating the clinical utility of multimodal large language models in rare maculopathy. ↗
pubmed · published 2025-12-03 · retrieved 2026-09-05T09:00:33Z
- Efficacy and safety of pentosan polysulfate therapy in patients with interstitial cystitis for relief of lower urinary tract symptoms: 15-year single center experience. ↗
pubmed · published 2025-12-01 · retrieved 2026-09-05T09:00:33Z
- Impact of Elmiron adjunct therapy on outcomes of fulguration in chronic interstitial cystitis in women. ↗
pubmed · published 2026-01-24 · retrieved 2026-09-05T09:00:33Z
- Effects of pentosan polysulfate sodium on synovial fluid biomarkers in moderate to severe knee osteoarthritis: an exploratory, phase 2, randomized, double-blind, placebo-controlled trial. ↗
pubmed · published 2026-01-26 · retrieved 2026-09-05T09:00:33Z
- Post-marketing safety of pentosan polysulfate sodium: a 21-year pharmacovigilance analysis of the FAERS database. ↗
pubmed · published 2025-01-01 · retrieved 2026-09-05T09:00:33Z
- Pentosan Polysulfate and Heparin Exhibit Comparable Interactions with Platelet Factor 4, Suggesting a Potential Risk of Thrombocytopenia. ↗
pubmed · published 2026-02-03 · retrieved 2026-09-05T09:00:33Z
- Effects of pentosan polysulfate sodium on joint structure and function out to six months in naturally-occurring canine osteoarthritis. ↗
pubmed · published 2026-01-01 · retrieved 2026-09-05T09:00:33Z
- Spectrum of Colopathy and Severe Polyposis Associated With Pentosan Polysulfate Sodium Maculopathy: A Retrospective Case Series. ↗
pubmed · published 2026-07-01 · retrieved 2026-08-29T08:37:13Z
- Late Development of Clinically Apparent Pentosan Polysulfate Maculopathy after Drug Cessation. ↗
pubmed · published 2026-04-01 · retrieved 2026-08-29T08:37:13Z
- Retinal Pigment Epithelium Injury in Pentosan Polysulfate Exposure: Morphologic Changes, Phagocytic Deficits, and Mitochondrial Dysfunction. ↗
pubmed · published 2026-03-31 · retrieved 2026-08-29T08:37:13Z
- Risk factors for pentosan polysulfate maculopathy. ↗
pubmed · published 2026-08-01 · retrieved 2026-08-29T08:37:13Z
- Retrospective study of visual acuity changes in patients with interstitial cystitis receiving pentosan polysulfate sodium. ↗
pubmed · published 2026-02-01 · retrieved 2026-09-05T09:00:33Z
- Characterization of Pentosan Polysulfate Sodium Maculopathy With Fluorescence Lifetime Imaging. ↗
pubmed · published 2026-05-15 · retrieved 2026-08-29T08:37:13Z
Publication history and provenance
Version 2 · Automated assessment · 2026-09-09T08:45:04Z
aa8c214c3bd4deca3cb2d782bbbdc8c7ce06ddde09e07003ca862c2753e7aa39